Toward a rational design of multitarget-directed antioxidants: merging memoquin and lipoic acid molecular frameworks.

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Journal of Medicinal Chemistry

• Publication date

  2009-10-08

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1021/jm901123nPMID 19813747
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Memoquin: A multi-target-directed ligand as an innovative therapeutic opportunity for Alzheimer’s disease

  2011cited by this paper
• MTDL design strategy in the context of Alzheimer's disease: from lipocrine to memoquin and beyond.

  2009cited by this paper
• Amyloid beta, mitochondrial dysfunction and synaptic damage: implications for cognitive decline in aging and Alzheimer's disease.

  2008cited by this paper
• Evaluation of Coenzyme Q as an Antioxidant Strategy for Alzheimer's Disease

  2008cited by this paper
• Oxidative stress triggers the amyloidogenic pathway in human vascular smooth muscle cells.

  2008cited by this paper
• Multi-target-directed ligands to combat neurodegenerative diseases.

  2008cited by this paper
• Novel class of quinone-bearing polyamines as multi-target-directed ligands to combat Alzheimer's disease.

  2007cited by this paper
• Lipoic acid as a novel treatment for Alzheimer's disease and related dementias.

  2007cited by this paper
• Congo red and protein aggregation in neurodegenerative diseases.

  2007cited by this paper
• A small molecule targeting the multifactorial nature of Alzheimer's disease.

  2007cited by this paper
• How to design multi-target drugs

  2007cited by this paper
• Causes of oxidative stress in Alzheimer disease

  2007cited by this paper
• The Effects and Mechanisms of Mitochondrial Nutrient α-Lipoic Acid on Improving Age-Associated Mitochondrial and Cognitive Dysfunction: An Overview

  2007cited by this paper
• Mitochondrial respiratory inhibition and oxidative stress elevate β-secretase (BACE1) proteins and activity in vivo in the rat retina

  2007cited by this paper
• Fragments, network biology and designing multiple ligands.

  2007cited by this paper
• Alpha-lipoic acid exhibits anti-amyloidogenicity for beta-amyloid fibrils in vitro.

  2006cited by this paper
• Preformed beta-amyloid fibrils are destabilized by coenzyme Q10 in vitro.

  2005cited by this paper
• Oxidative stress in the brain: novel cellular targets that govern survival during neurodegenerative disease.

  2005cited by this paper
• Rational approach to discover multipotent anti-Alzheimer drugs.

  2005cited by this paper
• Causes and consequences of oxidative stress in Alzheimer's disease.

  2002cited by this paper
• Quinone reductase (NQO1), a sensitive redox indicator, is increased in Alzheimer's disease.

  1999cited by this paper
• Dihydrolipoic acid maintains ubiquinone in the antioxidant active form by two-electron reduction of ubiquinone and one-electron reduction of ubisemiquinone.

  1999cited by this paper
• Oxidative stress hypothesis in Alzheimer's disease.

  1997cited by this paper

• Lipoic acid scaffold applications in the design of multitarget-directed ligands against Alzheimer's disease.

  2025cites this paper
• The Evolution of AChE Inhibitors in Alzheimer's Disease: From Single‐Target to Multi‐Target Ligands

  2025cites this paper
• Synthesis and evaluation of lipoic acid - donepezil hybrids for Alzheimer's disease using a straightforward strategy.

  2024cites this paper
• Quinones as Neuroprotective Agents

  2023cites this paper
• Mechanistic Insights for Drug Repurposing and the Design of Hybrid Drugs for Alzheimer's Disease.

  2022cites this paper
• Systematic In Silico Design, Synthesis, and Biological Studies of Some Novel 1,4-Benzoquinone Derivatives for the Prospective Management of Cognitive Decline.

  2021cites this paper
• Sulfur-containing therapeutics in the treatment of Alzheimer’s disease

  2021cites this paper
• Small Molecule Drugs for Treatment of Alzheimer’s Diseases Developed on the Basis of Mechanistic Understanding of the Serotonin Receptors 4 and 6

  2021cites this paper
• 1,2-Dithioles

  2021cites this paper
• Marine Natural Products, Multitarget Therapy and Repurposed Agents in Alzheimer’s Disease

  2020cites this paper
• A REVIEW ON EDARAVONE AS POTENTIAL ANTIOXIDANTS

  2020cites this paper
• Multi-Target Drug Candidates for Multifactorial Alzheimer’s Disease: AChE and NMDAR as Molecular Targets

  2020cites this paper
• Inhibitory Potency of 4- Substituted Sampangine Derivatives toward Cu2+ mediated aggregation of amyloid β-peptide, Oxidative Stress, and Inflammation in Alzheimer's Disease.

  2020cites this paper
• Anti-cholinesterase hybrids as multi-target-directed ligands against Alzheimer's disease (1998-2018).

  2019cites this paper
• Novel multi target-directed ligands targeting 5-HT4 receptors with in cellulo antioxidant properties as promising leads in Alzheimer's disease.

  2019cites this paper
• Chain Breaking Antioxidant Activity of Heavy (S, Se, Te) Chalcogens Substituted Polyphenols

  2019cites this paper
• New amyloid beta-disaggregating agents: synthesis, pharmacological evaluation, crystal structure and molecular docking of N-(4-((7-chloroquinolin-4-yl)oxy)-3-ethoxybenzyl)amines.

  2018cites this paper
• From catechol‐tocopherol to catechol‐hydroquinone polyphenolic antioxidant hybrids

  2018cites this paper
• Design of Multi-target Directed Ligands as a Modern Approach for the Development of Innovative Drug Candidates for Alzheimer’s Disease

  2018cites this paper
• Changing Paradigm from one Target one Ligand Towards Multi-target Directed Ligand Design for Key Drug Targets of Alzheimer Disease: An Important Role of In Silico Methods in Multi-target Directed Ligands Design

  2018cites this paper
• A molecular approach in drug development for Alzheimer's disease.

  2018cites this paper
• Novel 3-phenylcoumarin-lipoic acid conjugates as multi-functional agents for potential treatment of Alzheimer's disease.

  2018cites this paper
• Alzheimer’s disease: How metal ions define β-amyloid function

  2017cites this paper
• Multitarget-Directed Antioxidants as Therapeutic Agents: Putting the Focus on the Oxidative Stress

  2017cites this paper
• Medicinal Chemistry of Hybrids for Neurodegenerative Diseases

  2017cites this paper
• Novel Multitarget Hybrid Compounds for the Treatment of Alzheimer's Disease.

  2017cites this paper
• Rational design, synthesis and biological screening of triazine-triazolopyrimidine hybrids as multitarget anti-Alzheimer agents.

  2017cites this paper
• DL-3-n-butylphthalide-Edaravone hybrids as novel dual inhibitors of amyloid-β aggregation and monoamine oxidases with high antioxidant potency for Alzheimer's therapy.

  2017cites this paper
• Hybrids: a new paradigm to treat Alzheimer’s disease

  2016cites this paper
• Recent progress in multifunctional metal chelators as potential drugs for Alzheimer's disease

  2016cites this paper
• Recent progress in repositioning Alzheimer's disease drugs based on a multitarget strategy.

  2016cites this paper
• Synthesis and screening of triazolopyrimidine scaffold as multi-functional agents for Alzheimer's disease therapies.

  2016cites this paper
• Progress in the Rational Design for Polypharmacology Drug.

  2016cites this paper
• Multitarget Drug Discovery and Polypharmacology

  2016cites this paper
• From Bitopic Inhibitors to Multitarget Drugs for the Future Treatment of Alzheimer's Disease.

  2015cites this paper
• MTDLs Design on AChE (Acetylcholinesterase) and β-Secretase (BACE-1): 3D-QSAR and Molecular Docking Studies

  2015cites this paper
• Neurodegenerative diseases – Understanding their molecular bases and progress in the development of potential treatments

  2015cites this paper
• Therapeutic applications of lipoic acid: a patent review (2011 – 2014)

  2014cites this paper
• Multi-Target Directed Drugs: A Modern Approach for Design of New Drugs for the treatment of Alzheimer’s Disease

  2014cites this paper
• Two diseases, one approach: multitarget drug discovery in Alzheimer's and neglected tropical diseases

  2014cites this paper
• Synthesis of New Lipoic Acid Conjugates and Evaluation of Their Free Radical Scavenging and Neuroprotective Activities

  2014cites this paper
• Quinolone-benzylpiperidine derivatives as novel acetylcholinesterase inhibitor and antioxidant hybrids for Alzheimer disease.

  2014cites this paper
• Oxidative stress in Alzheimer's disease: are we connecting the dots?

  2014cites this paper
• Multitarget ligands and theranostics: sharpening the medicinal chemistry sword against prion diseases.

  2014cites this paper
• Multitarget drug design strategy: quinone-tacrine hybrids designed to block amyloid-β aggregation and to exert anticholinesterase and antioxidant effects.

  2014cites this paper
• Optimization of Gradient Chromatofocusing for the Protein Separation and LC-MS/MS Determination of NGP1-01 in Mouse Serum, Brain, and Retina

  2013cites this paper
• Multi-target compounds acting in the central nervous system designed from natural products.

  2013cites this paper
• Rationally designed multi-targeted agents against neurodegenerative diseases.

  2013cites this paper
• Recent advances in the multitarget‐directed ligands approach for the treatment of Alzheimer's disease

  2013influential citation
• Quinones bearing non-steroidal anti-inflammatory fragments as multitarget ligands for Alzheimer's disease.

  2013cites this paper
• Dual inhibitors of β-amyloid aggregation and acetylcholinesterase as multi-target anti-Alzheimer drug candidates.

  2013cites this paper
• Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.

  2012cites this paper
• Huprine Derivatives as Sub‐Nanomolar Human Acetylcholinesterase Inhibitors: From Rational Design to Validation by X‐ray Crystallography

  2012cites this paper
• Perspectives on the development of antioxidant antiepileptogenic agents.

  2012cites this paper
• Designed multiple ligands: basic research vs clinical outcomes.

  2012cites this paper
• Inhibition of cholinesterase activity and amyloid aggregation by berberine-phenyl-benzoheterocyclic and tacrine-phenyl-benzoheterocyclic hybrids.

  2012cites this paper
• Multitargeted Drugs for Treatment of Alzheimer's Disease

  2012cites this paper
• The art of building multifunctional metal-binding agents from basic molecular scaffolds for the potential application in neurodegenerative diseases

  2012cites this paper
• Therapeutic approaches for prion diseases and related neurogenerative disorders

  2011cites this paper
• Exploiting the lipoic acid structure in the search for novel multitarget ligands against Alzheimer's disease.

  2011cites this paper
• Cognitive Enhancers in Moderate to Severe Alzheimer's Disease:

  2011cites this paper
• Hybrid Lipoic Acid Derivatives to Attack Prion Disease on Multiple Fronts

  2011cites this paper
• The emergence of designed multiple ligands for neurodegenerative disorders.

  2011cites this paper
• The use of multi-target drugs in the treatment of neurodegenerative diseases

  2011cites this paper
• Multitarget-directed ligands: innovative chemical probes and therapeutic tools against Alzheimer's disease.

  2011cites this paper
• Reversible human serum albumin binding of lipocrine: a circular dichroism study.

  2011cites this paper
• Multitargeted drugs discovery: balancing anti-amyloid and anticholinesterase capacity in a single chemical entity.

  2011cites this paper
• Synthesis of monomeric derivatives to probe memoquin's bivalent interactions.

  2011cites this paper
• Strategies for the Inhibition of Protein Aggregation in Human Diseases

  2010cites this paper
• Parallel synthesis, evaluation, and preliminary structure-activity relationship of 2,5-diamino-1,4-benzoquinones as a novel class of bivalent anti-prion compound.

  2010cites this paper
• Oxidative stress: Biomarkers and novel therapeutic pathways

  2010cites this paper
• Wnt1 neuroprotection translates into improved neurological function during oxidant stress and cerebral ischemia through AKT1 and mitochondrial apoptotic pathways.

  2010cites this paper